RESUMO
3-Deazauridine (NSC 126849) is a structural analog of uridine that inhibits the biosynthesis of Cytidine-5'-Triphosphate by competitive inhibition of Cytidine Triphosphate synthetase which is considered to be the primary mode of action of this nucleoside analog. Despite a paucity of clinical attention given to this drug as a single agent, it has generated much enthusiasm as a biological response modulator because of its synergistic effect with a number of antitumor agents including Cytosine Arabinoside, 5-aza-2'-deoxycytidine, 5-azacytidine, thymidine and D-galactosamine, although only the cytosine arabinoside/3-Deazauridine combination has been explored clinically. In this paper, the current status of the drug and future perspectives will be discussed.
Assuntos
3-Desazauridina/farmacologia , Antineoplásicos/farmacologia , Uridina/análogos & derivados , 3-Desazauridina/metabolismo , 3-Desazauridina/uso terapêutico , 3-Desazauridina/toxicidade , Doença Aguda , Animais , Antineoplásicos/metabolismo , Antineoplásicos/uso terapêutico , Antineoplásicos/toxicidade , Azacitidina/análogos & derivados , Azacitidina/farmacologia , Citarabina/farmacologia , Decitabina , Avaliação de Medicamentos , Sinergismo Farmacológico , Galactosamina/farmacologia , Humanos , Cinética , Leucemia/tratamento farmacológico , Neoplasias/tratamento farmacológico , Timidina/farmacologiaRESUMO
Primary mediastinal germinomas in females are rare. Long-term survival ranges from 50 to 81%, depending on the initial extent of disease. Initial spread occurs intrathoracically and to regional nodes with late hematogenous dissemination. The roles of surgery, radiation therapy, and chemotherapy are discussed.
Assuntos
Disgerminoma/cirurgia , Neoplasias do Mediastino/cirurgia , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Disgerminoma/diagnóstico por imagem , Disgerminoma/radioterapia , Feminino , Seguimentos , Humanos , Neoplasias do Mediastino/diagnóstico por imagem , Neoplasias do Mediastino/radioterapia , RadiografiaRESUMO
A phase I trial of chlorozotocin was completed for a weekly times four dose schedule repeated every 8 weeks. Thrombocytopenia was the acute dose limiting toxicity. Nausea and vomiting were moderate to severe and dose related. Two cases of possible drug related irreversible nephrotoxicity were seen. Transient elevations of serum creatinine and mild proteinuria were noted. Also, transient elevations in SGOT were observed. One patient with a carcinoid tumor had a 60% reduction in his 5HIAA level after one course of therapy. The recommended dose for phase II clinical studies of chlorozotocin is 40 mg/m2 IV weekly for four weeks, repeated every 8 weeks.
